Fidelity Investments’s iShares US Pharmaceuticals ETF IHE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2M | Buy |
20,171
+357
| +2% | +$32.2K | ﹤0.01% | 2752 |
|
|
2026
Q1 | $1.72M | Buy |
19,814
+5,022
| +34% | +$440K | ﹤0.01% | 2691 |
|
|
2025
Q4 | $1.25M | Buy |
14,792
+1,890
| +15% | +$151K | ﹤0.01% | 2766 |
|
|
2025
Q3 | $936K | Buy |
12,902
+1,005
| +8% | +$69.3K | ﹤0.01% | 2814 |
|
|
2025
Q2 | $780K | Sell |
11,897
-206
| -2% | -$13.4K | ﹤0.01% | 2806 |
|
|
2025
Q1 | $854K | Sell |
12,103
-1,222
| -9% | -$84.9K | ﹤0.01% | 2729 |
|
|
2024
Q4 | $876K | Sell |
13,325
-256
| -2% | -$17.6K | ﹤0.01% | 2716 |
|
|
2024
Q3 | $959K | Buy |
13,581
+1,338
| +11% | +$93.2K | ﹤0.01% | 2613 |
|
|
2024
Q2 | $812K | Buy |
12,243
+2,117
| +21% | +$139K | ﹤0.01% | 2586 |
|
|
2024
Q1 | $687K | Buy |
10,126
+3,265
| +48% | +$216K | ﹤0.01% | 2620 |
|
|
2023
Q4 | $424K | Buy |
6,861
+2,451
| +56% | +$144K | ﹤0.01% | 2729 |
|
|
2023
Q3 | $260K | Sell |
4,410
-477
| -10% | -$29.3K | ﹤0.01% | 2805 |
|
|
2023
Q2 | $292K | Sell |
4,887
-741
| -13% | -$44.1K | ﹤0.01% | 2832 |
|
|
2023
Q1 | $329K | Buy |
5,628
+294
| +6% | +$17.7K | ﹤0.01% | 2828 |
|
|
2022
Q4 | $331K | Sell |
5,334
-1,446
| -21% | -$87K | ﹤0.01% | 2856 |
|
|
2022
Q3 | $383K | Buy |
6,780
+543
| +9% | +$33.4K | ﹤0.01% | 2862 |
|
|
2022
Q2 | $398K | Buy |
6,237
+378
| +6% | +$24K | ﹤0.01% | 2914 |
|
|
2022
Q1 | $379K | Buy |
5,859
+540
| +10% | +$34.2K | ﹤0.01% | 3072 |
|
|
2021
Q4 | $354K | Buy |
5,319
+540
| +11% | +$34.2K | ﹤0.01% | 2854 |
|
|
2021
Q3 | $291K | Hold |
4,779
| – | – | ﹤0.01% | 2889 |
|
|
2021
Q2 | $295K | Sell |
4,779
-192
| -4% | -$11.7K | ﹤0.01% | 2868 |
|
|
2021
Q1 | $295K | Sell |
4,971
-204
| -4% | -$12.3K | ﹤0.01% | 2764 |
|
|
2020
Q4 | $309K | Sell |
5,175
-645
| -11% | -$36.8K | ﹤0.01% | 2730 |
|
|
2020
Q3 | $317K | Sell |
5,820
-24
| -0.4% | -$1.29K | ﹤0.01% | 2618 |
|
|
2020
Q2 | $300K | Sell |
5,844
-123
| -2% | -$6.18K | ﹤0.01% | 2559 |
|
|
2020
Q1 | $268K | Buy |
5,967
+1,479
| +33% | +$74.6K | ﹤0.01% | 2530 |
|
|
2019
Q4 | $239K | Buy |
4,488
+1,635
| +57% | +$80.6K | ﹤0.01% | 2605 |
|
|
2019
Q3 | $133K | Sell |
2,853
-1,233
| -30% | -$59K | ﹤0.01% | 2703 |
|
|
2019
Q2 | $205K | Buy |
4,086
+18
| +0.4% | +$890 | ﹤0.01% | 2634 |
|
|
2019
Q1 | $209K | Sell |
4,068
-69
| -2% | -$3.43K | ﹤0.01% | 2582 |
|
|
2018
Q4 | $194K | Sell |
4,137
-534
| -11% | -$27.4K | ﹤0.01% | 2558 |
|
|
2018
Q3 | $261K | Buy |
+4,671
| New | +$255K | ﹤0.01% | 2614 |
|
|
2013
Q3 | – | Sell |
-296,067
| Closed | -$9.83M | – | 2641 |
|
|
2013
Q2 | $9.83M | Buy |
+296,067
| New | +$9.84M | ﹤0.01% | 1934 |
|
Other funds holding IHE
IWS
Fidelity Investments's IHE Position: Q2 2026 in Review
Fidelity Investments increased its iShares US Pharmaceuticals ETF (IHE) stake by 1.8% in Q2 2026, buying an estimated $32.2K and bringing the position to 20,171 shares worth $2M. The position accounts for ﹤0.01% of the portfolio, ranked #2752.
Fidelity Investments first reported a position in IHE in Q2 2013 and has held it in 33 quarters since. The position peaked at $9.83M in Q2 2013. 209 funds tracked by Wall St. Rank hold IHE as of Q2 2026.
- Fidelity Investments held 20,171 shares of iShares US Pharmaceuticals ETF worth $2M as of Q2 2026.
- Fidelity Investments bought 357 iShares US Pharmaceuticals ETF shares in Q2 2026, an estimated $32.2K.
- iShares US Pharmaceuticals ETF made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #2752 holding.
- Fidelity Investments first reported a position in iShares US Pharmaceuticals ETF in Q2 2013 and has held it in 33 quarters since.
- Fidelity Investments's iShares US Pharmaceuticals ETF position peaked at $9.83M in Q2 2013.
- 209 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q2 2026.
Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.